Pharvaris presents data on deucrictibant for hereditary angioedema treatment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026
June 15, 2026 6:50 AM EDTResults from prespecified assessment of End of Progression in the RAPIDe-3 Phase 3 study and clinical relevance of this newly-defined endpoint detailed in an oral presentationEvidence on the cardiovascular safety profile of deucrictibant in clinical studies to date presented
ZUG, Switzerland, June 15, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq:... More
